S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   358.77 (+0.24%)
AAPL   175.63 (+0.48%)
MSFT   316.56 (-0.14%)
META   300.00 (+0.31%)
GOOGL   130.83 (+0.45%)
AMZN   130.89 (+1.37%)
TSLA   246.22 (+0.55%)
NVDA   420.40 (+1.03%)
NIO   8.35 (-2.11%)
BABA   86.97 (-1.51%)
AMD   97.06 (+0.89%)
T   15.05 (-0.46%)
F   12.57 (+1.13%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.37%)
GE   111.56 (+0.28%)
DIS   80.94 (-0.38%)
AMC   8.12 (+6.56%)
PFE   32.93 (+0.73%)
PYPL   58.70 (+1.42%)
NFLX   383.59 (+1.00%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   358.77 (+0.24%)
AAPL   175.63 (+0.48%)
MSFT   316.56 (-0.14%)
META   300.00 (+0.31%)
GOOGL   130.83 (+0.45%)
AMZN   130.89 (+1.37%)
TSLA   246.22 (+0.55%)
NVDA   420.40 (+1.03%)
NIO   8.35 (-2.11%)
BABA   86.97 (-1.51%)
AMD   97.06 (+0.89%)
T   15.05 (-0.46%)
F   12.57 (+1.13%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.37%)
GE   111.56 (+0.28%)
DIS   80.94 (-0.38%)
AMC   8.12 (+6.56%)
PFE   32.93 (+0.73%)
PYPL   58.70 (+1.42%)
NFLX   383.59 (+1.00%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   358.77 (+0.24%)
AAPL   175.63 (+0.48%)
MSFT   316.56 (-0.14%)
META   300.00 (+0.31%)
GOOGL   130.83 (+0.45%)
AMZN   130.89 (+1.37%)
TSLA   246.22 (+0.55%)
NVDA   420.40 (+1.03%)
NIO   8.35 (-2.11%)
BABA   86.97 (-1.51%)
AMD   97.06 (+0.89%)
T   15.05 (-0.46%)
F   12.57 (+1.13%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.37%)
GE   111.56 (+0.28%)
DIS   80.94 (-0.38%)
AMC   8.12 (+6.56%)
PFE   32.93 (+0.73%)
PYPL   58.70 (+1.42%)
NFLX   383.59 (+1.00%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   358.77 (+0.24%)
AAPL   175.63 (+0.48%)
MSFT   316.56 (-0.14%)
META   300.00 (+0.31%)
GOOGL   130.83 (+0.45%)
AMZN   130.89 (+1.37%)
TSLA   246.22 (+0.55%)
NVDA   420.40 (+1.03%)
NIO   8.35 (-2.11%)
BABA   86.97 (-1.51%)
AMD   97.06 (+0.89%)
T   15.05 (-0.46%)
F   12.57 (+1.13%)
MU   68.43 (-0.65%)
CGC   0.93 (+10.37%)
GE   111.56 (+0.28%)
DIS   80.94 (-0.38%)
AMC   8.12 (+6.56%)
PFE   32.93 (+0.73%)
PYPL   58.70 (+1.42%)
NFLX   383.59 (+1.00%)
NYSE:MRK

Merck & Co., Inc. (MRK) Stock Forecast, Price & News

$105.81
-0.53 (-0.50%)
(As of 03:52 PM ET)
Compare
Today's Range
$105.11
$106.19
50-Day Range
$105.00
$111.34
52-Week Range
$85.29
$119.65
Volume
3.33 million shs
Average Volume
7.57 million shs
Market Capitalization
$268.49 billion
P/E Ratio
86.73
Dividend Yield
2.76%
Price Target
$124.74

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.74 Rating Score
Upside/​Downside
18.2% Upside
$124.74 Price Target
Short Interest
Healthy
0.58% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.33
Upright™ Environmental Score
News Sentiment
1.07mentions of Merck & Co., Inc. in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$937,998 Sold Last Quarter
Proj. Earnings Growth
180.86%
From $3.03 to $8.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.95 out of 5 stars

Medical Sector

36th out of 961 stocks

Pharmaceutical Preparations Industry

9th out of 456 stocks


MRK stock logo

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. is a US-based multinational pharmaceutical and healthcare company. It was officially founded in 1891 as the US arm of Merck Group, headquartered in Germany. Merck Group was founded in 1668 when Friedrick Jacob Merck purchased a pharmacy in Darmstadt, Germany. The company transformed from a pharmacy into a drug manufacturer in 1827 with the commercialization of morphine and the perfection of the manufacturing process. The company will later gain recognition for isolating and commercializing the manufacture of cocaine as well.

Merck Group sent Theodore Weicker to New York as its representative in 1889 and he quickly began to set up operations. The original investment of $200,000 resulted in a facility in lower Manhattan and the addition of Merck family member George Merck to the project. They began operations in 1891 and were in business as the US branch of Merck Group until 1917 and the onset of World War I.

World War I brought about the Trading With The Enemy Act of 1917 and the nationalization of Merck Group’s US operations. Those operations were repurchased at a government auction only 2 years later with the help of Goldman Sachs and Lehman Brothers, but the split was done. The company retained rights to the Merck name in the US but remained independent. One of many noteworthy achievements in the post-War period is the discovery of streptomycin, which was revolutionary in treating tuberculosis.

In 1953 the company merged with Sharp& Dohme to form the then 2nd largest US drug manufacturer. The merger brought smallpox vaccines to the portfolio and opened a new avenue of research for the business. Since then, advancements in vaccine technology include treatments for mumps and chickenpox. Other notable advancements include the discovery of statins as a cholesterol inhibitor and work in veterinary medicine.

Today, Merck & Co operates through 2 segments and under 2 different names with a headquarters in Kenilworth, NJ.  The company operates as Merck & Co in the US and as Merck Sharp & Dohme outside the US and Canada. The 2 segments are Pharmaceutical and Animal Health. Revenue topped $49 billion in 2022 and employed more than 68,000 people. The company has 8 research facilities near major university systems, including 7 in the US and 1 in the UK. As of 2022, the company had 82 pipeline products in Phase 2 trials, 30 in Phase 3 trials and 3 under review.

The Pharmaceutical segment researches discover and commercializes human health products in several areas of medicine. These include but are not limited to oncology, acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. This segment has 6 blockbuster drugs as of late 2022, with each generating more than $1 billion in revenue. The leading treatments are Keytruda for treating cancer-related immune conditions, Gardisil which is a vaccine for HPV and Januvia for treating Type-II diabetes. The Animal Health segment discovers, develops, manufactures, and markets veterinary healthcare products and services. Both segments sell to healthcare facilities and distributors.

MRK Price History

MRK Stock News Headlines

Flee to Healthcare Stocks if Recession Rears its Head? (MRK)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (MRK)
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company
Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>
Merck (MRK) Stock Moves -0.05%: What You Should Know
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company
Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>
Is Merck (NYSE:MRK) A Risky Investment?
Reasons for the Rise of Merck & Co. (MRK) in Q2
Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK)
See More Headlines
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Company Calendar

Ex-Dividend for 7/10 Dividend
6/14/2023
Dividend Payable
7/10/2023
Last Earnings
8/01/2023
Ex-Dividend for 10/6 Dividend
9/14/2023
Today
9/25/2023
Dividend Payable
10/06/2023
Next Earnings (Confirmed)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
69,000
Year Founded
1891

Price Target and Rating

Average Stock Price Forecast
$124.74
High Stock Price Forecast
$135.00
Low Stock Price Forecast
$113.00
Forecasted Upside/Downside
+17.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.74
Research Coverage
19 Analysts

Profitability

Net Income
$14.52 billion
Pretax Margin
9.28%

Debt

Sales & Book Value

Annual Sales
$59.28 billion
Cash Flow
$9.03 per share
Book Value
$18.17 per share

Miscellaneous

Outstanding Shares
2,537,520,000
Free Float
2,532,446,000
Market Cap
$269.84 billion
Optionable
Optionable
Beta
0.33

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Robert M. Davis J.D.Mr. Robert M. Davis J.D. (Age 56)
    Chairman, Pres & CEO
    Comp: $6.08M
  • Ms. Caroline LitchfieldMs. Caroline Litchfield (Age 54)
    Exec. VP & CFO
    Comp: $2.8M
  • Ms. Jennifer L. Zachary (Age 45)
    Exec. VP & Gen. Counsel
    Comp: $2.73M
  • Dr. Dean Y. Li M.D. (Age 61)
    Ph.D., Exec. VP & Pres of Merck Research Laboratories
    Comp: $3.44M
  • Mr. Chirfi Guindo (Age 57)
    Sr. VP & Chief Marketing Officer for Merck Human Health
    Comp: $1.54M
  • Mr. David Michael Williams (Age 54)
    Exec. VP and Chief Information & Digital Officer
  • Mr. Peter Dannenbaum
    VP of Investor Relations
  • Lisa LeCointe-Cephas (Age 41)
    Sr. VP and Chief Ethics & Compliance Officer
  • Ms. Cristal N. Downing (Age 53)
    Exec. VP and Chief Communications & Public Affairs Officer
  • Mr. Steven C. MizellMr. Steven C. Mizell (Age 63)
    Exec. VP & Chief HR Officer













MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 5 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRK shares.
View MRK analyst ratings
or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2023?

19 Wall Street analysts have issued 1-year target prices for Merck & Co., Inc.'s stock. Their MRK share price forecasts range from $113.00 to $135.00. On average, they predict the company's share price to reach $124.74 in the next year. This suggests a possible upside of 17.3% from the stock's current price.
View analysts price targets for MRK
or view top-rated stocks among Wall Street analysts.

How have MRK shares performed in 2023?

Merck & Co., Inc.'s stock was trading at $110.95 at the start of the year. Since then, MRK stock has decreased by 4.2% and is now trading at $106.34.
View the best growth stocks for 2023 here
.

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our MRK earnings forecast
.

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, October 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings data on Tuesday, August, 1st. The company reported ($2.06) earnings per share for the quarter, beating analysts' consensus estimates of ($2.18) by $0.12. The business had revenue of $15.04 billion for the quarter, compared to analyst estimates of $14.44 billion. Merck & Co., Inc. had a net margin of 5.34% and a trailing twelve-month return on equity of 16.29%. The business's revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.87 earnings per share.
Read the conference call transcript
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 25th. Shareholders of record on Friday, September 15th will be given a dividend of $0.73 per share on Friday, October 6th. This represents a $2.92 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Thursday, September 14th.
Read our dividend analysis for MRK
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.92 per share and currently has a dividend yield of 2.75%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 239.34%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MRK will have a dividend payout ratio of 34.31% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY23 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $2.95-3.05 for the period, compared to the consensus EPS estimate of $2.90. The company issued revenue guidance of $58.6-59.6 billion, compared to the consensus revenue estimate of $58.67 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (73.31%), State Street Corp (4.67%), Geode Capital Management LLC (2.08%), Charles Schwab Investment Management Inc. (1.21%), Northern Trust Corp (1.13%) and Bank of New York Mellon Corp (1.05%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Johannes Jacobus Oosthuizen, Joseph Romanelli, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Steven Mizell.
View institutional ownership trends
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $106.34.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $269.84 billion and generates $59.28 billion in revenue each year. The company earns $14.52 billion in net income (profit) each year or $1.22 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

The company employs 69,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -